Dossier AMM conditionnelle pour astrazenca
- 25/02/2021
Partager cet article
Share on facebook
Share on linkedin
Share on twitter
Share on email
COVID-19 Vaccine AstraZeneca
Product Information as approved by the CHMP on 29 January 2021, pending endorsement by the European Commission
Includes:
Package leaflet (for patients)
Summary of product characteristics (for healthcare professionals) Manufacturers and conditions of the marketing authorisation Labelling
Références & liens
https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021-pending-endorsement_en.pdf